aid: scorpion-therapeutics
name: Scorpion Therapeutics
description: 'Scorpion Therapeutics is a clinical-stage precision oncology biotechnology company
  founded in 2020 and headquartered in Boston, Massachusetts. It pursued what it called Precision
  Oncology 2.0 — integrating target discovery, medicinal chemistry and translational medicine to
  produce mutant-selective small-molecule cancer drugs — led by STX-478, an oral mutant-selective
  PI3K-alpha inhibitor in Phase 1/2 trials for breast cancer and other advanced solid tumors, and
  STX-721, a covalent EGFR/HER2 exon 20 inhibitor. In January 2025 Eli Lilly agreed to acquire
  Scorpion and its PI3K-alpha program in a transaction valued at up to $2.5 billion, with the
  non-PI3K-alpha pipeline and staff spun into a separate independent company. Scorpion is a drug
  developer, not a software vendor: it publishes no API, SDK, developer portal or machine-readable
  specification, and its own domain now redirects to the acquirer''s announcement.'
image: https://avatars.githubusercontent.com/u/73207155?v=4
url: https://raw.githubusercontent.com/api-evangelist/scorpion-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-05'
modified: '2026-08-05'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Precision Medicine
- Drug Discovery
- Life Sciences
- Clinical Research
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/scorpion-therapeutics-domain-security.yml
- type: Website
  url: https://www.scorpiontx.com/
- type: GitHubOrganization
  url: https://github.com/scorpiontx
- type: LinkedIn
  url: https://www.linkedin.com/company/scorpiontherapeutics
- type: Press
  url: https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-scorpion-therapeutics-mutant-selective-pi3ka
x-enrichment:
  date: '2026-08-05'
  status: minimal
  artifacts_added: 1
  pass: local-v1
x-coverage:
  state: none
  reason: defunct
  detail: Scorpion's own site no longer serves the company — https://www.scorpiontx.com/
    302-redirects every request to Eli Lilly's January 2025 acquisition press release,
    and the only first-party technical surface left is a four-repo GitHub org of
    computational-chemistry forks and an STX-721 molecular-dynamics data-availability
    README, with no API, SDK or spec anywhere.
  evidence:
  - url: https://www.scorpiontx.com/
    status: 302
  - url: https://www.scorpiontx.com/openapi.json
    status: 404
  - url: https://www.scorpiontx.com/llms.txt
    status: 404
  - url: https://www.scorpiontx.com/.well-known/agent-card.json
    status: 403
  - url: https://api.github.com/orgs/scorpiontx
    status: 200
  checked: '2026-08-05'